ITLN1 and hepatocellular carcinoma: Collectively, the authors proposed ITLN1 as a dual-purpose molecule: (i) a predictive marker of LF sensitivity and (ii) a therapeutic target through which ligand-based or mimetic therapies might be developed to enhance apoptosis, cell-cycle control, and angiogenesis suppression in HCC [51].